A Randomized Trial to Assess Whether Co-creating Patient Educational Materials With Patients Has Added Value Over Researchers and Clinicians Developing Patient Education Materials and Engaging Patients During Usability Testing Only.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Patient Educational Materials
- Sponsor
- Unity Health Toronto
- Enrollment
- 573
- Locations
- 1
- Primary Endpoint
- Pretest-posttest change in prostate cancer screening decisional conflict and intention to be screened between the co-created PEM group and the traditional PEM group.
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
Although the harms of screening for prostate cancer with the prostate-specific antigen (PSA) test outweigh the benefits, 560,000 Ontario men undergo PSA screening each year. Guideline developers, such as the Canadian Task Force on Preventive Health Care (CTFPHC), have disseminated patient educational materials (PEMs) on PSA screening widely in Ontario, yet men remain confused about screening harms and benefits. One potential contributing factor may be that PEMs are typically developed by researchers and clinicians and may not address patient barriers to change. The investigators will assess whether a PSA screening PEM that is co-created with patients provides added value over PEMs developed using the traditional approach (i.e., researchers and clinicians develop a PEM with patient involvement in usability testing only. The investigators will also assess satisfaction with the engagement process and calculate the costs and resources required for each method (i.e. co-creation, usability, and recommendations only). This study will generate a PSA screening PEM to help patients make evidence-based screening decisions. It will also help Ontario organizations, including Cancer Care Ontario, identify optimal methods for developing PEMs for PSA screening and other areas of preventive health care, such as breast and colorectal cancer screening.
Investigators
Eligibility Criteria
Inclusion Criteria
- •English-speaking men aged 40+ years will be eligible to take part in the project if they have never been diagnosed with prostate cancer and do not have any signs or symptoms of prostate cancer.
Exclusion Criteria
- •Individuals will not be eligible for the project if they indicate that they are a health care professional or have any conflicts of interest relevant to the guideline topic (e.g., owning shares in a company related to prostate cancer treatment).
Outcomes
Primary Outcomes
Pretest-posttest change in prostate cancer screening decisional conflict and intention to be screened between the co-created PEM group and the traditional PEM group.
Time Frame: This measure will be assessed from date of randomization until date of survey completion, assessed up to 1 month.
The investigators will assess differences and changes in prostate cancer screening decisional conflict and intention to be screened for the co-created PEM group and the traditional PEM group using repeated measures ANOVAs.
Secondary Outcomes
- Pretest-posttest change in knowledge of prostate cancer screening(This measure will be assessed from date of randomization until date of survey completion, assessed up to 1 month.)
- Comparison of PEM usability(This measure will be assessed from date of randomization until date of survey completion, assessed up to 1 month.)
- Participant preference of PEM(This measure will be assessed from date of randomization until date of survey completion, assessed up to 1 month)
- Resources use for PEM development(This measure will be assessed after the intervention (survey) is administered (i.e., post analysis), up to 1 month.)